Hepatitis C Virus Transmission Dynamics in Injection Drug Users
- 1 January 1998
- journal article
- review article
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 33 (5) , 1197-1212
- https://doi.org/10.3109/10826089809062214
Abstract
Hepatitis C virus (HCV) presents several challenges to the development of prevention programs. HCV infection is persistent in up to 80% of cases, and viremic individuals may transmit infection to others. With 65-90% of injection drug users anti-HCV positive, a large reservoir of infection exists in most drug-injector populations. Studying the genetic variability of HCV infections could permit researchers to reconstruct chains of viral transmission in IDUs. However, the relationship of HCV to HIV epidemiology remains unclear and may depend on whether the proportions of infectious persons in the population are similar for both viruses.Keywords
This publication has 36 references indexed in Scilit:
- Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program.American Journal of Public Health, 1995
- Spread of bloodborne viruses among Australian prison entrantsBMJ, 1995
- Transmission of the hepatitis-C virus by tissue transplantation.Journal of Bone and Joint Surgery, 1995
- Hepatitis C Serotype and Response to Interferon TherapyNew England Journal of Medicine, 1994
- Hepatitis C virus genotypes: An investigation of type-specific differences in geographic origin and diseaseHepatology, 1994
- Sexual transmission of hepatitis C virusThe Lancet, 1993
- Lack of Protective Immunity Against Reinfection with Hepatitis C VirusScience, 1992
- Application of Blood Transfusion Guidelines in a Major Hospital of Kinshasa, ZaireAIDS, 1992
- The Incidence of HBV Infection and Syringe Exchange ProgramsJAMA, 1991
- Effects of Amsterdam Needle and Syringe ExchangeInternational Journal of the Addictions, 1991